Bone Turnover Marker Changes During and After Short-term Glucocorticoid Treatment in People With Inflammatory Joint Diseases The BOOGIE Study

What this Trial Is About

Researchers are studying how bone turnover markers BTMs change during and after short-term glucocorticoid treatment in patients with inflammatory joint diseases like rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. The study aims to improve understanding of BTM reliability during glucocorticoid use, since these medications suppress BTMs and increase fracture risk. This knowledge could help optimize patient care and reduce side effects and healthcare costs. Participants include those newly diagnosed with inflammatory joint diseases starting disease-modifying antirheumatic drugs DMARDs, some with glucocorticoid bridging and others without, as well as patients on stable DMARD treatment receiving glucocorticoid injections. Patients are grouped by disease type, glucocorticoid use, and agemenopausal status. Bone turnover markers P1NP and CTX1 will be measured every 4 weeks up to 6 months after the last glucocorticoid dose. During the study, researchers will track bone marker levels to assess their changes over time after stopping glucocorticoids or during inflammation treatment without glucocorticoids. The main measurement is P1NP level 3 months after stopping glucocorticoids, with additional measures up to 6 months. This observational study will follow patients for several months to better understand BTM dynamics and improve osteoporosis management in this population.

Dynamics in Bone Turnover Markers During and After Short-term Glucocorticoid Treatment in Patients With an Inflammatory Joint Disease